Benedict Gierl
Psychiatry · Oak Park, ILNPI 1649397969
Payments from drug & device makers
Across 400 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Avanir Pharmaceuticals, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- AbbVie$979
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$866
- Teva Pharmaceuticals USA, Inc.$840
- plus $3K from 9 others
What the payments were for
- Food & beverage$8,91396%
- Education$3424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 44 | $1,437 |
| Avanir Pharmaceuticals, Inc. | 84 | $1,236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $1,120 |
| AbbVie(2 entities) | 42 | $979 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $866 |
| Teva Pharmaceuticals USA, Inc. | 30 | $840 |
| Urovant Sciences Inc | 47 | $823 |
| Acadia Pharmaceuticals Inc | 24 | $595 |
| Sunovion Pharmaceuticals Inc. | 30 | $542 |
| Otsuka America Pharmaceutical, Inc. | 11 | $404 |
| Lundbeck LLC | 15 | $219 |
| Vanda Pharmaceuticals Inc. | 6 | $137 |
| Alkermes, Inc. | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,255 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 16 | $95,537 |
| GemtesaVibegron | 38 | $7,849 |
| Divalproex Sodium | 30 | $2,572 |
| Memantine Hcl | 75 | $1,029 |
| Quetiapine Fumarate | 71 | $601 |
| Gabapentin | 59 | $429 |
| Mirtazapine | 38 | $378 |
| Fluoxetine Hcl | 15 | $194 |
| Lamotrigine | 37 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $840 | $95,53716 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $15 | $7,84938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Oak Park
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.